5th JOINT MEETING BELGIAN-DUTCH NEUROMUSCULAR STUDY GROUP AND GERMAN REFERENCE CENTER FOR NEUROMUSCULAR DISEASES, DGNN

19-20 APRIL, 2024

HOTEL KASTEEL BLOEMENDAL
VAALS, THE NETHERLANDS



PROGRAM Friday 19 April 2024

08:30 - 09:00 Registration (coffee/tea)
09:00 - 09:10 Welcome (J. Weis, K. Claeys)
09:10 - 10:36 **SESSION 1: Motor neuron diseases**
Chairpersons: Bjarne Udd, Michael Van Es
Therapeutic (r)evolution in SMA: where are we now and what about the future? - *Liesbeth De Waele (Belgium)*
Novel developments in ALS - *Michael Van Es (The Netherlands)*

Oral presentations from abstracts
Bi-allelic ATXN2 repeat expansions cause autosomal, recessive ALS - *Koen Demaegd*
The German MND-Net Tissue Bank - an update - *Joachim Weis*
Risdiplam treatment in adult patients with spinal muscular atrophy: a prospective study investigating clinical, functional, and patient-reported outcome measures over 12 months - *Louise Iterbeke*

10:36 - 11:00 **Coffee break**

11:00 - 12:13 **SESSION 2: Neuromuscular junction disorders**
Chairpersons: Marc De Baets, Mario Losen
Update on Myasthenia gravis – optimizing treatment for all patients - *Martijn Tannemaat (The Netherlands)*

Oral presentations from abstracts
Congenital myasthenic syndromes in Belgium: genetic and clinical characterization of pediatric and adult patients - *Nathalie Smeets*
The relevance of complement activation in myasthenia gravis – a quantification study using the experimental passive transfer MG model - *Anja Schöttler*
Hock immunization, an update of the experimental autoimmune myasthenia gravis (EAMG) mouse model - *Marina Mané Damas*
Are thymus-resident plasma cells prognostic factors of thymectomy in patients with anti-acetylcholine receptor myasthenia gravis? - *Britt Arets*

12:13 - 13:00 A tribute to Prof. J. Michael Schröder, 1935-2023 *(Joachim Weis. Stephan Züchner, Claudia Sommer, Vincent Timmerman, Hans-Hilmar Goebel)*

13:00 - 14:00 **Lunch**

14:00 - 16:39 **SESSION 3: Peripheral neuropathies I**
Chairpersons: Claudia Sommer, Peter Van den Bergh
New EAN/PNS GBS guideline - *Pieter Van Doorn (The Netherlands)*
Pathophysiology of demyelinating neuropathies - *Ruth Stassart (Germany)*
Genomics-To-Therapy: a concept illustrated by CMT-SORD - *Stephan Züchner (USA)*

Oral presentations from abstracts

Supervised machine learning algorithms for diagnosing chronic inflammatory demyelinating polyradiculoneuropathy - *Iris van Doorn*

Loss-of-function mutations in the nuclear envelope gene FAM169A cause autosomal dominant lower and upper motor neuropathy - *Maike Dohrn*

Recurrent missense variant in ITPR3 causes demyelinating Charcot-Marie-Tooth neuropathy with remarkably variable severity - *Danique Beijer*

Frequency and clinical characterization of SORD-Related neuropathy in a Belgian cohort - *Matthias Opsomer*

Dominant OGDH mutations cause peripheral neuropathy with ataxia and optical atrophy - *Liedewei Van de Vondel*

Let's drop some Fats: The idiosyncrasies of lipid droplets in iPSC-Schwann cell precursor cells from Charcot-Marie-Tooth disease type 1A patients. - *Koen Kuipers*

Inducible dental pulp stem cells-derived Schwann cells for CMT1A modelling - *Nathalie Dirkx*

16:39 - 17:00 **Coffee break**

17:00 - 19:14 **SESSION 4: Peripheral neuropathies II**

Chairpersons: Martin Lammens, Stephan Goedee

Novel therapeutic avenues in hereditary peripheral neuropathies - *Davide Pareyson (Italy)*

Proteostasis regulators in neuromuscular diseases – learning from zebrafish models - *Juliane Bremer (Germany)*

Oral presentations from abstracts

Comparison of efficacy outcomes with Vutrisiran vs. Patisiran in hATTR amyloidosis with polyneuropathy: post-hoc analysis of the HELIOS-A study - *Valérie Dupong*

A comparison of neurofilament in serum, cerebrospinal fluid and peripheral nerve in patients undergoing nerve biopsy - *Simon Streit*

Autophagy phenotypical screening identified new molecules to restore neuronal proteostasis in cellular models of HSPB1 and HSPB8-associated peripheral neuropathies - *Angela Sisto*

The effects of PMP22 overexpression on cellular stress in Charcot-Marie-Tooth disease type 1A - *Hanne Jeurissen*

PDE4D inhibition with Gebr32a stimulates Schwann cell differentiation and improves the functional outcome in models for Charcot Marie Tooth disease 1A - *Tim Vangansewinkel*

Foreign body response hampers tissue integration of a poly(ε-caprolactone) nanofibre-containing scaffold for peripheral nerve repair - *Pascal Achenbach*

Nerve transfers in children with Arthrogryposis Multiplex Congenita - *Benedikt Schäfer*

19:30 **Dinner**

PROGRAM Saturday 20 April 2024

08:30 - 10:33 **SESSION 5: Muscle disorders I**

Chairpersons: Werner Stenzel, Anne Schänzer

Neuromuscular imaging: a better eye on nerves and muscles - *Nens van Alfen (The Netherlands)*

Clinical and imaging advances in inflammatory myopathies - *Anneke van der Kooi (The Netherlands)*

Whats New in Pathogenesis of IIM - *Werner Stenzel (Germany)*

Oral presentations from abstracts

The adiponectin receptor agonist, ALY688: a promising therapeutic for fibrosis in the dystrophic muscle - *Nicolas Dubuisson*

Inhibition of KDM5A reverses pathological features in sporadic inclusion body myositis-like cell models - *Geert de Vries*

Automated morphometric analysis of ICAM-1 expression highlights similarities and differences between myositis subtypes - *Anne Schänzer*

10:33 - 11:00 **Coffee break**

11:00 - 13:05 **SESSION 6: Muscle disorders II**

Chairpersons: Ingo Kurth, Anneke Van der Kooi

Genetics in distal muscle diseases - *Bjarne Udd (Finland)*

Advances and caveats of novel therapies in (neuro)muscular disorders - *Benedikt Schoser (Germany)*

Oral presentations from abstracts

Comprehensive four-year disease progression assessment of DM1, based on the Dutch MYODRAFT registry - *Leandre la Fontaine*

Life expectancy and causes of death in patients with Myotonic Dystrophy type 2. - *Alide Tieleman*

Heterozygous SPTAN1 loss-of-function variants cause early childhood onset distal myopathy - *Jonathan De Winter*

The exception that proves the rule: a titin truncating variant causing a dominant myopathy with cardiac involvement - *Kristl Claeys*

Alpha-synuclein as potential biomarker in Inclusion body myositis – a histological and serological study - *Alexander Mensch*

13:05 - 13:10 **Closure** (J. Weis, K. Claeys)

13:10 **Lunch**